MYC and c-MYC deregulation is common in PDA, with ∼30% of primary and metastatic tumors showing MYC amplification.28 In a small sample size, Schleger et al. were able to identify two patients with high MYC amplification in the metastatic site when compared with the primary tumor, which had low MYC amplification.28 There was strong correlation between MYC amplification and protein expression and tumor grade in this population as well, demonstrating its role in PDA progression. This evidence concerns the gene MYC and Patent ductus arteriosus.